49 related articles for article (PubMed ID: 37752540)
1. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract][Full Text] [Related]
2. Dynamic surveillance of lymphocyte subsets in patients with non-small cell lung cancer during chemotherapy or combination immunotherapy for early prediction of efficacy.
Zhen S; Wang W; Qin G; Lu T; Yang L; Zhang Y
Front Immunol; 2024; 15():1316778. PubMed ID: 38482008
[TBL] [Abstract][Full Text] [Related]
3. Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.
Wang Y; Ma L; Chen Y; Yun W; Yu J; Meng X
Cancer Sci; 2024 Apr; ():. PubMed ID: 38590234
[TBL] [Abstract][Full Text] [Related]
4. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8
Gicobi JK; Mao Z; DeFranco G; Hirdler JB; Li Y; Vianzon VV; Dellacecca ER; Hsu MA; Barham W; Yan Y; Mansfield AS; Lin Y; Wu X; Hitosugi T; Owen D; Grams MP; Orme JJ; Lucien F; Zeng H; Park SS; Dong H
Sci Adv; 2023 Nov; 9(46):eadi2414. PubMed ID: 37967193
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo-like Lesions as a Predictor of Response to Immunotherapy in Non-Small Cell Lung Cancer: Comprehensive Review and Case Series from a University Center.
Coelho JQ; Romão R; Sousa MJ; Azevedo SX; Fidalgo P; Araújo A
Curr Oncol; 2024 Feb; 31(2):1113-1128. PubMed ID: 38392077
[TBL] [Abstract][Full Text] [Related]
6. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
8. [Peripheral Blood Laboratory Test Results Combined with TCF1+CD8+ T Lymphocytes
Ratio to Predict the Response and Prognosis of Immunotherapy to
Advanced Lung Cancer].
Luo H; Dai S; Li Y; Tian P; Li Q; Cai X
Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):605-614. PubMed ID: 37752540
[TBL] [Abstract][Full Text] [Related]
9. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
Yan Y; Wang X; Liu C; Jia J
BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
[TBL] [Abstract][Full Text] [Related]
10. Associations between peripheral blood lymphocyte subsets and clinical outcomes in patients with lung cancer treated with immune checkpoint inhibitor.
Li P; Qin P; Fu X; Zhang G; Yan X; Zhang M; Zhang X; Yang J; Wang H; Ma Z
Ann Palliat Med; 2021 Mar; 10(3):3039-3049. PubMed ID: 33849094
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
Front Immunol; 2022; 13():912180. PubMed ID: 35844502
[TBL] [Abstract][Full Text] [Related]
12. Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients.
Mazzaschi G; Minari R; Zecca A; Cavazzoni A; Ferri V; Mori C; Squadrilli A; Bordi P; Buti S; Bersanelli M; Leonetti A; Cosenza A; Ferri L; Rapacchi E; Missale G; Petronini PG; Quaini F; Tiseo M
Lung Cancer; 2020 Oct; 148():1-11. PubMed ID: 32768804
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors.
Zhang Z; Yuan F; Chen R; Li Y; Ma J; Yan X; Wang L; Zhang F; Tao H; Guo D; Huang Z; Zhang S; Li X; Zhi X; Ge X; Hu Y; Wang J
Front Immunol; 2020; 11():1173. PubMed ID: 32587591
[No Abstract] [Full Text] [Related]
14. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy.
Luoma AM; Suo S; Wang Y; Gunasti L; Porter CBM; Nabilsi N; Tadros J; Ferretti AP; Liao S; Gurer C; Chen YH; Criscitiello S; Ricker CA; Dionne D; Rozenblatt-Rosen O; Uppaluri R; Haddad RI; Ashenberg O; Regev A; Van Allen EM; MacBeath G; Schoenfeld JD; Wucherpfennig KW
Cell; 2022 Aug; 185(16):2918-2935.e29. PubMed ID: 35803260
[TBL] [Abstract][Full Text] [Related]
15. CD8
Duchemann B; Naigeon M; Auclin E; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Desnoyer A; Danlos FX; Mezquita L; Caramella C; Marabelle A; Besse B; Chaput N
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131864
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]